These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34294862)

  • 1. Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria.
    Charbonneau MR; Denney WS; Horvath NG; Cantarella P; Castillo MJ; Puurunen MK; Brennan AM
    Commun Biol; 2021 Jul; 4(1):898. PubMed ID: 34294862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria.
    Isabella VM; Ha BN; Castillo MJ; Lubkowicz DJ; Rowe SE; Millet YA; Anderson CL; Li N; Fisher AB; West KA; Reeder PJ; Momin MM; Bergeron CG; Guilmain SE; Miller PF; Kurtz CB; Falb D
    Nat Biotechnol; 2018 Oct; 36(9):857-864. PubMed ID: 30102294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.
    Puurunen MK; Vockley J; Searle SL; Sacharow SJ; Phillips JA; Denney WS; Goodlett BD; Wagner DA; Blankstein L; Castillo MJ; Charbonneau MR; Isabella VM; Sethuraman VV; Riese RJ; Kurtz CB; Brennan AM
    Nat Metab; 2021 Aug; 3(8):1125-1132. PubMed ID: 34294923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering.
    Adolfsen KJ; Callihan I; Monahan CE; Greisen PJ; Spoonamore J; Momin M; Fitch LE; Castillo MJ; Weng L; Renaud L; Weile CJ; Konieczka JH; Mirabella T; Abin-Fuentes A; Lawrence AG; Isabella VM
    Nat Commun; 2021 Oct; 12(1):6215. PubMed ID: 34711827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial.
    Vockley J; Sondheimer N; Puurunen M; Diaz GA; Ginevic I; Grange DK; Harding C; Northrup H; Phillips JA; Searle S; Thomas JA; Zori R; Denney WS; Ernst SL; Humphreys K; McWhorter N; Kurtz C; Brennan AM
    Nat Metab; 2023 Oct; 5(10):1685-1690. PubMed ID: 37770764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip.
    Nelson MT; Charbonneau MR; Coia HG; Castillo MJ; Holt C; Greenwood ES; Robinson PJ; Merrill EA; Lubkowicz D; Mauzy CA
    Nat Commun; 2021 May; 12(1):2805. PubMed ID: 33990606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic etiology and clinical challenges of phenylketonuria.
    Elhawary NA; AlJahdali IA; Abumansour IS; Elhawary EN; Gaboon N; Dandini M; Madkhali A; Alosaimi W; Alzahrani A; Aljohani F; Melibary EM; Kensara OA
    Hum Genomics; 2022 Jul; 16(1):22. PubMed ID: 35854334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Of mice and men: Plasma phenylalanine reduction in PKU corrects neurotransmitter pathways in the brain.
    Berguig GY; Martin NT; Creer AY; Xie L; Zhang L; Murphy R; Pacheco G; Bullens S; Olbertz J; Weng HH
    Mol Genet Metab; 2019 Dec; 128(4):422-430. PubMed ID: 31648944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral administration of phenylalanine molecularly imprinted polymer (MIP) benefits PKU mouse model.
    Torab M; Jafari-Sabet M; Najafizadeh P; Sadegipour A; Rahimi-Moghaddam P; Ebrahimi SA
    J Inherit Metab Dis; 2022 Jul; 45(4):696-709. PubMed ID: 35527480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria.
    Leuzzi V; Bianchi MC; Tosetti M; Carducci CL; Carducci CA; Antonozzi I
    J Inherit Metab Dis; 2000 Sep; 23(6):563-70. PubMed ID: 11032331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the phenylalanine hydroxylase gene on maternal phenylketonuria outcome.
    Güttler F; Azen C; Guldberg P; Romstad A; Hanley WB; Levy HL; Matalon R; Rouse BM; Trefz F; de la Cruz F; Koch R
    Pediatrics; 2003 Dec; 112(6 Pt 2):1530-3. PubMed ID: 14654659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-year retrospective analysis of patients with phenylketonuria (PKU) and hyperphenylalaninemia treated at two specialized clinics.
    Levy H; Lamppu D; Anastosoaie V; Baker JL; DiBona K; Hawthorne S; Lindenberger J; Kinch D; Seymour A; McIlduff M; Watling S; Vockley J
    Mol Genet Metab; 2020 Mar; 129(3):177-185. PubMed ID: 31883647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycomacropeptide, a low-phenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria.
    Solverson P; Murali SG; Brinkman AS; Nelson DW; Clayton MK; Yen CL; Ney DM
    Am J Physiol Endocrinol Metab; 2012 Apr; 302(7):E885-95. PubMed ID: 22297302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of sapropterin on urinary monoamine metabolites in phenylketonuria.
    Douglas TD; Jinnah HA; Bernhard D; Singh RH
    Mol Genet Metab; 2013 Jul; 109(3):243-50. PubMed ID: 23712020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Over Restriction of Dietary Protein Allowance: The Importance of Ongoing Reassessment of Natural Protein Tolerance in Phenylketonuria.
    Pinto A; Almeida MF; MacDonald A; Ramos PC; Rocha S; Guimas A; Ribeiro R; Martins E; Bandeira A; Jackson R; van Spronsen F; Payne A; Rocha JC
    Nutrients; 2019 Apr; 11(5):. PubMed ID: 31052331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1H MR chemical shift imaging detection of phenylalanine in patients suffering from phenylketonuria (PKU).
    Sijens PE; Oudkerk M; Reijngoud DJ; Leenders KL; de Valk HW; van Spronsen FJ
    Eur Radiol; 2004 Oct; 14(10):1895-900. PubMed ID: 15378255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma phenylalanine concentrations are associated with hepatic iron content in a murine model for phenylketonuria.
    Gropper SS; Yannicelli S; White BD; Medeiros DM
    Mol Genet Metab; 2004 May; 82(1):76-82. PubMed ID: 15110326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary glycomacropeptide supports growth and reduces the concentrations of phenylalanine in plasma and brain in a murine model of phenylketonuria.
    Ney DM; Hull AK; van Calcar SC; Liu X; Etzel MR
    J Nutr; 2008 Feb; 138(2):316-22. PubMed ID: 18203898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New protein structures provide an updated understanding of phenylketonuria.
    Jaffe EK
    Mol Genet Metab; 2017 Aug; 121(4):289-296. PubMed ID: 28645531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria.
    Elsas LJ; Greto J; Wierenga A
    Mol Genet Metab; 2011 Apr; 102(4):407-12. PubMed ID: 21216643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.